Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …

γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen
presentation, which makes them a highly promising effector cell compartment for cancer …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Summary Gut interleukin-17A (IL-17)-producing γδ T cells are tissue-resident cells that are
involved in both host defense and regulation of intestinal inflammation. However, factors that …

Immune-based therapies such as immune checkpoint inhibitors have revolutionized the
systemic treatment of various cancer types. The therapeutic application of monoclonal …

Lung cancer is closely associated with chronic inflammation, but the causes of inflammation
and the specific immune mediators have not been fully elucidated. The lung is a mucosal …

Interferon-gamma (IFN-γ) is a pleiotropic molecule with associated antiproliferative, pro-
apoptotic and antitumor mechanisms. This effector cytokine, often considered as a major …

As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of
immunotherapy in recent years. They have extraordinary antitumor potential and prospects …

Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly
require the presence of αβT cells that recognize tumour neoantigens, and are therefore …